EMA Authorised: Cibinqo (abrocitinib) — Pfizer Europe MA EEIG

View source ↗

Summary

EMA confirms authorisation of Cibinqo (abrocitinib) for atopic dermatitis in Europe.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Cibinqo (abrocitinib)

Snippet

Status: Authorised. Therapeutic area: Dermatitis, Atopic. MAH: Pfizer Europe MA EEIG. Decision date: 23/06/2025